BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Blisibimod: Interim Phase IIb data

Interim data from the double-blind, placebo-controlled, international Phase IIb PEARL-SC trial showed that subcutaneous blisibimod significantly reduced B cells. Details were not disclosed. Anthera said elevations in B cells have been associated with an increased risk of disease activity in lupus...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >